These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 33378048)

  • 1. Gut microbiota and its metabolic potential.
    Czajkowska A; Kaźmierczak-Siedlecka K; Jamioł-Milc D; Gutowska I; Skonieczna-Żydecka K
    Eur Rev Med Pharmacol Sci; 2020 Dec; 24(24):12971-12977. PubMed ID: 33378048
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gut microbial metabolites in obesity, NAFLD and T2DM.
    Canfora EE; Meex RCR; Venema K; Blaak EE
    Nat Rev Endocrinol; 2019 May; 15(5):261-273. PubMed ID: 30670819
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolic-Dysfunction-Associated Fatty Liver Disease and Gut Microbiota: From Fatty Liver to Dysmetabolic Syndrome.
    Abenavoli L; Scarlata GGM; Scarpellini E; Boccuto L; Spagnuolo R; Tilocca B; Roncada P; Luzza F
    Medicina (Kaunas); 2023 Mar; 59(3):. PubMed ID: 36984595
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Understanding the Role of the Gut Microbiome and Microbial Metabolites in Obesity and Obesity-Associated Metabolic Disorders: Current Evidence and Perspectives.
    Vallianou N; Stratigou T; Christodoulatos GS; Dalamaga M
    Curr Obes Rep; 2019 Sep; 8(3):317-332. PubMed ID: 31175629
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gut Microbiota as a Therapeutic Target for Metabolic Disorders.
    Okubo H; Nakatsu Y; Kushiyama A; Yamamotoya T; Matsunaga Y; Inoue MK; Fujishiro M; Sakoda H; Ohno H; Yoneda M; Ono H; Asano T
    Curr Med Chem; 2018; 25(9):984-1001. PubMed ID: 28990516
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protective effect of quercetin on high-fat diet-induced non-alcoholic fatty liver disease in mice is mediated by modulating intestinal microbiota imbalance and related gut-liver axis activation.
    Porras D; Nistal E; Martínez-Flórez S; Pisonero-Vaquero S; Olcoz JL; Jover R; González-Gallego J; García-Mediavilla MV; Sánchez-Campos S
    Free Radic Biol Med; 2017 Jan; 102():188-202. PubMed ID: 27890642
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Contribution of the gut microbiota to the regulation of host metabolism and energy balance: a focus on the gut-liver axis.
    Delzenne NM; Knudsen C; Beaumont M; Rodriguez J; Neyrinck AM; Bindels LB
    Proc Nutr Soc; 2019 Aug; 78(3):319-328. PubMed ID: 30628563
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of Bile Acids in Metabolic Control.
    Molinaro A; Wahlström A; Marschall HU
    Trends Endocrinol Metab; 2018 Jan; 29(1):31-41. PubMed ID: 29195686
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting the gut microbiota with resveratrol: a demonstration of novel evidence for the management of hepatic steatosis.
    Wang P; Wang J; Li D; Ke W; Chen F; Hu X
    J Nutr Biochem; 2020 Jul; 81():108363. PubMed ID: 32388250
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of the gut microbiome and its metabolites in metabolic diseases.
    Wu J; Wang K; Wang X; Pang Y; Jiang C
    Protein Cell; 2021 May; 12(5):360-373. PubMed ID: 33346905
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gut Microbiota and Nonalcoholic Fatty Liver Disease: Insights on Mechanism and Application of Metabolomics.
    He X; Ji G; Jia W; Li H
    Int J Mol Sci; 2016 Mar; 17(3):300. PubMed ID: 26999104
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gut microbiota-mediated generation of saturated fatty acids elicits inflammation in the liver in murine high-fat diet-induced steatohepatitis.
    Yamada S; Kamada N; Amiya T; Nakamoto N; Nakaoka T; Kimura M; Saito Y; Ejima C; Kanai T; Saito H
    BMC Gastroenterol; 2017 Nov; 17(1):136. PubMed ID: 29187142
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Review article: emerging role of the gut microbiome in the progression of nonalcoholic fatty liver disease and potential therapeutic implications.
    Jayakumar S; Loomba R
    Aliment Pharmacol Ther; 2019 Jul; 50(2):144-158. PubMed ID: 31149745
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interactions between Gut Microbiota and Natural Bioactive Polysaccharides in Metabolic Diseases: Review.
    Pi Y; Fang M; Li Y; Cai L; Han R; Sun W; Jiang X; Chen L; Du J; Zhu Z; Li X
    Nutrients; 2024 Aug; 16(17):. PubMed ID: 39275156
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The intestinal microbiome and metabolic diseases : From obesity to diabetes and nonalcoholic steatohepatitis].
    Bischoff SC
    Internist (Berl); 2017 May; 58(5):441-448. PubMed ID: 28432400
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The mechanism of berberine alleviating metabolic disorder based on gut microbiome.
    Wang H; Zhang H; Gao Z; Zhang Q; Gu C
    Front Cell Infect Microbiol; 2022; 12():854885. PubMed ID: 36093200
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Correlation analysis of gut microbiota and biochemical indexes in patients with non-alcoholic fatty liver disease].
    Ren SM; Mei L; Huang H; Cao SF; Zhao RH; Zheng PY
    Zhonghua Gan Zang Bing Za Zhi; 2019 May; 27(5):369-375. PubMed ID: 31177662
    [No Abstract]   [Full Text] [Related]  

  • 18. Gut Microbiota and Nonalcoholic Fatty Liver Disease: Insights on Mechanisms and Therapy.
    Ma J; Zhou Q; Li H
    Nutrients; 2017 Oct; 9(10):. PubMed ID: 29035308
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disruptions in gut microbial-host co-metabolism and the development of metabolic disorders.
    Rajani C; Jia W
    Clin Sci (Lond); 2018 Apr; 132(7):791-811. PubMed ID: 29661926
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gut Microbiota and Metabolic Disorders: Advances in Therapeutic Interventions.
    Akash MSH; Fiayyaz F; Rehman K; Sabir S; Rasool MH
    Crit Rev Immunol; 2019; 39(4):223-237. PubMed ID: 32421966
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.